Evonik achieves major biotech breakthrough with a new animal-free and fermentation-based collagen platform

Recombinant collagen mimics attributes of human collagen

19-Mar-2020 - Evonik announced the development of an advanced collagen platform that is made via fermentation-based processes and devoid of animal- or human-derived materials. The recombinant technology will, for the first time, provide pharmaceutical, medical, cell culture and tissue engineering markets with ...

CO2 for a clean performance: Rheticus research project by Evonik and Siemens enters phase 2

High-value specialty chemicals produced from CO2 and water using electricity from renewable sources and bacteria

14-Oct-2019 - Evonik and Siemens launched their joint research project Rheticus II. The goal is to develop an efficient and powerful test plant that will use carbon dioxide and water as well as electricity from renewable sources and bacteria to produce specialty chemicals (CO2). In the Rheticus I project, the ...

Evonik is investing in NUMAFERM

Start-up makes the production of peptides more efficient

21-Sep-2017 - Through its Venture Capital unit, Evonik has invested in the start-up NUMAFERM and now holds a minority share in the spin-off of Heinrich Heine University Düsseldorf. The investment was made as part of a seed financing round and also includes investments by High-Tech Gründerfonds, the Business ...

Evonik commercializes biosurfactants

22-Jun-2016 - Evonik is commercializing biosurfactants: the specialty chemicals company is now the first in the world to use biotech methods for producing industrial-scale quantities of high- quality surfactants—key components of modern shampoos, shower gels, and household cleansers. The achievement has been ...

Evonik acquires share in JeNaCell

08-Jul-2015 - Evonik has for the first time acquired shares in a young technology company in Germany via its venture capital arm. The Group invested in JeNaCell GmbH and now holds a minority share in the spin-off of Friedrich Schiller University in Jena. JeNaCell is a specialist for nanocellulose generated ...

Industrial chromatography and reverse osmosis optimize amino acid fermentation process

06-Feb-2015 - Using creativity and unconventional ideas, researchers and engineers at Evonik have achieved a significant breakthrough in the biotechnological production of amino acids based on fermentation. They integrated the separating methods of chromatography and reverse osmosis and an online analytical ...

Evonik invests in the biotechnology company Algal Scientific

30-Apr-2014 - Evonik Industries is investing in the technology startup Algal Scientific Corporation (Northville, Michigan, USA). Evonik is part of an investors’ consortium that is investing more than US$3 million in Series A financing round. Under the trade name AlgamuneTM Algal markets 1,3-β-glucan, a ...

Bacteria like the taste of syngas

A milestone for third-generation biotechnology

06-Dec-2013 - For the first time, Evonik Industries has managed to use biotech methods to convert syngas to pure 2-hydroxyisobutyric acid (2-HIBA) under industrial conditions. 2-HIBA is a precursor used in the manufacture of PLEXIGLAS®. Waste gas is one example of a source of syngas. "We have shown that there ...

Evonik invests heavily in biotech

Patrik Wohlhauser, member of the Executive Board: “In the Health & Nutrition Business Unit alone we hope to see sales of €1 billion by 2020 from products made using biotechnology.”

11-Oct-2012 - Evonik Industries plans to continue expanding its commitment to biotechnology. “Biotech opens up interesting opportunities for profitable growth in a range of business areas,” says Patrik Wohlhauser, a member of the Executive Board. “It’s also giving Evonik’s growth strategy a stronger focus on ...

Evonik establishes joint venture in Russia to produce feed amino acid L-lysine

Growing demand for biotechnology-manufactured L-lysine in Russia

05-Oct-2011 - Evonik Industries and Russian company RusBiotech International have established the joint venture Russkie Biotechnologii for manufacturing L-lysine in Russia by means of a biotechnological process. Vassily Golubev, governor of the Rostov-on-Don region, and Vadim Varshavsky, a deputy of the State ...